Clinical Trials Logo

Relapsed Acute Myeloid Leukemia clinical trials

View clinical trials related to Relapsed Acute Myeloid Leukemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05028751 Terminated - Clinical trials for Acute Myeloid Leukemia

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Start date: August 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML).

NCT ID: NCT02109627 Terminated - Clinical trials for Acute Myeloid Leukemia

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Start date: May 1, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard treatment for AML, is safe to give to patients and to determine the best dose to give. The study doctors want to see what effects, good and/or bad, the study drug has on subjects and their AML. The study will look at what side effects subjects may have and how subjects feel after receiving the study drug.